CONTEXT: In longitudinal studies of adults, elevated amino acid (AA) concentrations predicted future type 2 diabetes mellitus (T2DM). OBJECTIVE: The aim of the present investigation was to examine whether increased plasma AA concentrations are associated with impaired β-cell function relative to insulin sensitivity [i.e. disposition index (DI)], a predictor of T2DM development. DESIGN, SETTING, AND PARTICIPANTS: Metabolomic analysis for fasting plasma AAs was performed by tandem mass spectrometry in 139 normal-weight and obese adolescents with and without dysglycemia. First-phase insulin secretion was evaluated by a hyperglycemic (∼225 mg/dl) clamp and insulin sensitivity by a hyperinsulinemic-euglycemic clamp. DI was calculated as the product of first-phase insulin and insulin sensitivity. RESULTS: DI was positively associated with branched-chain AAs (leucine/isoleucine and valine; r = 0.27 and 0.29, P = 0.001), neutrally transported AAs (phenylalanine and methionine; r = 0.30 and 0.35, P < 0.001), basic AAs (histidine and arginine; r = 0.28 and 0.23, P ≤ 0.007), serine (r = 0.35, P < 0.001), glycine (r = 0.26, P = 0.002), and branched-chain AAs-derived intermediates C3, C4, and C5 acylcarnitine (range r = 0.18-0.19, P ≤ 0.04). CONCLUSION: In youth, increased plasma AA concentrations are not associated with a heightened metabolic risk profile for T2DM; rather, they are positively associated with β-cell function relative to insulin sensitivity. These contrasting observations between adults and youth may be a reflection of developmental differences along the lifespan dependent on the combined impact of the aging process together with the impact of progressive obesity.
CONTEXT: In longitudinal studies of adults, elevated amino acid (AA) concentrations predicted future type 2 diabetes mellitus (T2DM). OBJECTIVE: The aim of the present investigation was to examine whether increased plasma AA concentrations are associated with impaired β-cell function relative to insulin sensitivity [i.e. disposition index (DI)], a predictor of T2DM development. DESIGN, SETTING, AND PARTICIPANTS: Metabolomic analysis for fasting plasma AAs was performed by tandem mass spectrometry in 139 normal-weight and obese adolescents with and without dysglycemia. First-phase insulin secretion was evaluated by a hyperglycemic (∼225 mg/dl) clamp and insulin sensitivity by a hyperinsulinemic-euglycemic clamp. DI was calculated as the product of first-phase insulin and insulin sensitivity. RESULTS: DI was positively associated with branched-chain AAs (leucine/isoleucine and valine; r = 0.27 and 0.29, P = 0.001), neutrally transported AAs (phenylalanine and methionine; r = 0.30 and 0.35, P < 0.001), basic AAs (histidine and arginine; r = 0.28 and 0.23, P ≤ 0.007), serine (r = 0.35, P < 0.001), glycine (r = 0.26, P = 0.002), and branched-chain AAs-derived intermediates C3, C4, and C5 acylcarnitine (range r = 0.18-0.19, P ≤ 0.04). CONCLUSION: In youth, increased plasma AA concentrations are not associated with a heightened metabolic risk profile for T2DM; rather, they are positively associated with β-cell function relative to insulin sensitivity. These contrasting observations between adults and youth may be a reflection of developmental differences along the lifespan dependent on the combined impact of the aging process together with the impact of progressive obesity.
Authors: Valeriya Lyssenko; Peter Almgren; Dragi Anevski; Roland Perfekt; Kaj Lahti; Michael Nissén; Bo Isomaa; Björn Forsen; Nils Homström; Carola Saloranta; Marja-Riitta Taskinen; Leif Groop; Tiinamaija Tuomi Journal: Diabetes Date: 2005-01 Impact factor: 9.461
Authors: Christopher B Newgard; Jie An; James R Bain; Michael J Muehlbauer; Robert D Stevens; Lillian F Lien; Andrea M Haqq; Svati H Shah; Michelle Arlotto; Cris A Slentz; James Rochon; Dianne Gallup; Olga Ilkayeva; Brett R Wenner; William S Yancy; Howard Eisenson; Gerald Musante; Richard S Surwit; David S Millington; Mark D Butler; Laura P Svetkey Journal: Cell Metab Date: 2009-04 Impact factor: 27.287
Authors: E S Tai; M L S Tan; R D Stevens; Y L Low; M J Muehlbauer; D L M Goh; O R Ilkayeva; B R Wenner; J R Bain; J J M Lee; S C Lim; C M Khoo; S H Shah; C B Newgard Journal: Diabetologia Date: 2010-01-15 Impact factor: 10.122
Authors: Wei Perng; Matthew W Gillman; Abby F Fleisch; Ryan D Michalek; Steven M Watkins; Elvira Isganaitis; Mary-Elizabeth Patti; Emily Oken Journal: Obesity (Silver Spring) Date: 2014-09-24 Impact factor: 5.002
Authors: Wei Perng; Ellen C Francis; Harry A Smith; John Carey; Dongqing Wang; Katerina M Kechris; Dana Dabelea Journal: J Clin Endocrinol Metab Date: 2020-09-01 Impact factor: 5.958
Authors: Wei Perng; Brandy M Ringham; Harry A Smith; Gregory Michelotti; Katerina M Kechris; Dana Dabelea Journal: Diabetologia Date: 2019-11-13 Impact factor: 10.122
Authors: Kevin R Short; Jennifer Q Chadwick; April M Teague; Mary A Tullier; Lisa Wolbert; Charlotte Coleman; Kenneth C Copeland Journal: J Clin Endocrinol Metab Date: 2019-08-01 Impact factor: 5.958